An update to the CRM1 cargo/NES database

NESdb

Ho Yee Joyce Fung, Ashley Niesman, and Yuh Min Chook*
Department of Pharmacology, UT Southwestern Medical Center, Dallas TX 75390

The nuclear export receptor CRM1 transports hundreds to thousands of diverse functioning macromolecules (proteins and RNAs) from the nucleus to the cytoplasm. CRM1 cargo proteins contain short 8–15 residue-long nuclear export signals (NESs) that bind directly to the NES-binding groove of CRM1. NES peptides are diverse in both sequence and structure; many match the classical $\Phi X_2 \Phi_2 X_2 \Phi_3 X_4$ consensus sequence pattern where $\Phi$ is Leu, Val, Ile, Phe, or Met and $X$ is any amino acid (classes 1a–d in Table 1). However, recent structural studies of CRM1 bound to NESs with diverse sequences significantly expanded the diversity of this sequence pattern, increasing variation of the number of $X$ residues to form different spacings between the four hydrophobic $\Phi$ residues (Fung et al., 2015, 2017) (Table 1). In 2012, we published the NESdb (http://prodata.swmed.edu/LRNes/index.php), a database of 221 NES-containing CRM1 cargoes (Xu et al., 2012). Each entry in NESdb displayed the sequence, structure, and experimental information on the putative NES sequence(s) of a previously reported CRM1 cargo. The NES entries were separated into two groups: “NESs” and “NESs in doubt.” Twenty-two of the 221 NESs were NESs in doubt entries, which included contradictory evidence that raised questions about the validity of the reported NESs. We have updated NESdb to a total of 399 entries. This letter describes the significant expansion of the database. We also highlight advances in NES identification that are important to consider for the search of NESs in potential CRM1 cargoes.

NESdb: an important resource for studying human diseases

Since the publication of NESdb in 2012, CRM1 has gained increasing importance in cancer biology. Many of its cargos are tumor suppressor, proapoptotic, and growth regulator proteins that can confer survival advantages to cancer cells when the dysregulated proteins are aberrantly mislocalized to the cytoplasm. Inhibition of CRM1 can restore mislocalized tumor suppressor proteins and growth regulators to the nucleus, where they can potentially mediate apoptosis in response to DNA damage, to the cell's microenvironment or to chemotherapy (Lapalombella et al., 2012; Etchin et al., 2013; Kim et al., 2016; Wang and Liu, 2019; Wang et al., 2020). A slowly reversible covalent inhibitor of CRM1 named Xpovio (Selinexor or KPT-330) has been shown to have broad antitumor activity that relies on cell type/context-dependent nuclear retention of a variety of CRM1 cargos (e.g., p53, IxB, NPM1, PAR-4, FOXO, p73, p27, topoisomerase IIa, MDM2, mTOR), causing subsequent activation of cell-cycle arrest and apoptotic-, anti-inflammatory-, and stress-related gene expression (Lapalombella et al., 2012; Etchin et al., 2013). Xpovio was recently approved for use to treat relapsed or refractory multiple myeloma and refractory diffuse large B-cell lymphoma. Xpovio and next generation analog Eltanexor are also being tested in many clinical trials for a variety of malignancies. It remains unclear which of the many CRM1 cargos are critical for cancer pathogenesis and are targeted by these CRM1 inhibitors in different cancers to enable therapeutic response.

In addition to cancer, CRM1 is also a drug target for other human diseases. CRM1-mediated export was found to be involved in neurodegenerative damage (Kim et al., 2010), and CRM1 levels are up-regulated in damaged brains in rat models and multiple sclerosis patients (Li et al., 2013; Haines et al., 2015). CRM1 inhibition to sequester proapoptotic and inflammatory proteins in the nucleus has therefore been explored as a strategy to treat traumatic brain injuries and inflammatory demyelination (Haines et al., 2015; Tajiri et al., 2016). Moreover, CRM1-mediated nuclear export is also critical in the replication of many viruses and CRM1 is thus a therapeutic target in viral diseases such as HIV, influenza, and COVID-19 (Perwitasari et al., 2014; Boons et al., 2015; Kashyap et al., 2016; Mathew and Ghildyal, 2017; Taylor et al., 2019; Gordon et al., 2020; Zhou et al., 2020). Xpovio is currently being tested in clinical trials for therapy in moderate or severe COVID-19 cases (NCT04349098/0434725).

All available CRM1 inhibitors inhibit the interaction of CRM1 with all NES-containing cargoes, and knowledge of key cargo targets that change the course of individual diseases is still lacking. It is therefore critical to understand CRM1-cargo/NES recognition more deeply and broadly. NES prediction remains a challenge as currently available predictors can only achieve ~50% precision (LocNES; Xu et al., 2015). NESdb remains a useful resource of reported CRM1 cargoes and NESs for researchers from various biomedical disciplines to determine if their proteins of interest contain NESs and are potential CRM1 cargoes. Here, we report a major update of NESdb.

An updated NESdb

Regular curation of the published literature for potential CRM1 cargoes and NESs has been ongoing since the NESdb was launched. Since 2012, we have curated 178 new entries to the database by
using “CRM1” and “Leptomycin B” (LMB) or “NES” as search terms in PubMed. The reported CRM1 cargo proteins in these new entries include 102 human, 17 nonhuman mammalian, 10 Xenopus laevis, 5 Drosophila melanogaster, 10 Saccharomyces cerevisiae, and 26 viral proteins from a variety of viruses; the remaining 8 proteins are from crabs, plants, fungi, and parasites. The new entries also include 17 new CRM1 cargoes categorized as “in doubt” because of missing or contradictory evidences related to CRM1 dependence. The format for displaying entries remains the same as described in the original publication.

Of the 178 new NESdb entries, 107 contain information of putative NESs that were experimentally tested and found to be sufficient to direct nuclear export as an isolated peptide; 38 of these experimentally tested NESs are also part of available PDB entries. The remaining 71 entries reported CRM1 dependency detected through various experimental methods, but the published works did not test or sufficiently demonstrate nuclear export activity of the putative NES peptides. New x-ray structures of NESs bound to CRM1 have been updated to their respective NESdb entries, and we will continue our efforts to include updates on new 3D structures for all entries. We have also improved the database to allow the pages to load more efficiently. NESdb will continue to be updated on a regular basis.

As we examined and compiled the 178 new NESdb entries, we noted two relevant recent advances in CRM1-NES research. First, recent structural studies of CRM1-NES complexes have significantly expanded the diversity of known NES consensus patterns. This is mostly due to the discovery of reverse NESs that are described by the consensus pattern $\Phi_1XX\Phi_2XX\Phi_3XX\Phi_4$, which is the reverse of the traditional $\Phi_1XX\Phi_2XX\Phi_3XX\Phi_4$ consensus pattern (classes 1a-R to 1d-R in Table 1). Crystal structures of CRM1 bound to two peptides with the reverse consensus, CPEB4NES and hRio2NES, showed the peptides binding the CRM1 groove in the opposite peptide direction (minus direction) compared with earlier identified NESs (plus direction) (Fung et al., 2015). Some subsequently published works have reported the search for putative reverse NESs and their identification in putative CRM1 cargoes SHIP2, UBXS, CEP43, CDC27, ZO-2, and Ubx (Dufraisse et al., 2020; Sendino et al., 2020). Future NES searches using these new sequence patterns will surely expand the current repertoire of NES sequences and CRM1 cargoes.

Second, only a small fraction of the publications that reported experimental validation of NESs considered the issue of NES accessibility within the full-length cargo proteins. Many reports of CRM1 cargoes/NESs, including those published between 2012 and 2020, lacked the perspective of the NES in context of the full-length cargo. Sequences that match NES consensus patterns are found in many if not most helix-containing proteins, but many of these sequences are buried in the hydrophobic cores of folded domains and thus are not accessible to bind CRM1. Simply testing nuclear export capabilities of putative NES peptides does not yield information on the full-length cargo, and mutating hydrophobic residues of the putative NESs may disrupt folded domains and artifically change their cellular localization. Results of these types of experiments must be interpreted with caution. For example, a well-established strong NES in the MEK1 kinase, which binds CRM1 with high affinity and effectively direct nuclear export as a peptide, was found to be only weakly functional in the full-length protein, likely due to part of the NES being buried in the folded protein (Baumhardt et al., 2020). Conversely, misfolding of the SOD1 protein causes exposure of a normally buried NES and subsequent CRM1-mediated export (Zhong et al., 2017). It is therefore important to study NES function within the full-length cargo and to consider new mechanisms for dynamic regulation of protein localization in cells.

We are confident that researchers from many biomedical research disciplines will find the updated NESdb useful, and we urge users of the database to provide input on the entries of their interest to assist with validation of the NESs. Use of NESdb in publications should cite the original publication: Xu D, Grishin NV, Chook YM. NESdb: a database of NES-containing CRM1 cargoes. Mol Biol Cell 2012 Sep;23(18):3673-6 and/or this Letter.

**ACKNOWLEDGMENTS**

We thank Darui Xu, Ming Tang, Szu-chin Fu, Binita Shakya, and Szymon Olejniczak for assistance in updating NESdb and Nick Grishin for hosting the newly migrated database. This work is funded by the Cancer Prevention Research Institute of Texas (CPRIT) Grants.

---

### Table 1: NES consensus sequences.

| Class | Consensus* | Number of residues between $\Phi$s | Select cargoes that bind CRM1 using this consensusb (NES ID in NESdb) |
|-------|------------|------------------------------------|---------------------------------------------------------------|
| 1a    | $\Phi_1XX\Phi_2XX\Phi_3XX\Phi_4$ | 3-2-1                             | PKI (5), MEK1 (11), HDAC5 (61), Paxillin (136), 4E-T (233)   |
| 1b    | $\Phi_1XX\Phi_2XX\Phi_3XX\Phi_4$ | 2-2-1                             | SNUPN (1)                                                     |
| 1c    | $\Phi_1XX\Phi_2XX\Phi_3XX\Phi_4$ | 3-3-1                             | HIV-Rev (2), SMAD4 (18), FMRP (22)                           |
| 1d    | $\Phi_1XX\Phi_2XX\Phi_3XX\Phi_4$ | 2-3-1                             | mDia2 (77), CDC7 (197)                                      |
| 2     | $\Phi_1XX\Phi_2XX\Phi_3XX\Phi_4$ | 1-2-1                             | X11L2 (141)                                                  |
| 3     | $\Phi_1XX\Phi_2XX\Phi_3XX\Phi_4$ | 2-3-2                             | hRio2 (153), CPEB4 (198)                                   |
| 1a-R  | $\Phi_1XX\Phi_2XX\Phi_3XX\Phi_4$ | 1-2-3                             |                                                              |
| 1b-R  | $\Phi_1XX\Phi_2XX\Phi_3XX\Phi_4$ | 1-2-2                             |                                                              |
| 1c-R  | $\Phi_1XX\Phi_2XX\Phi_3XX\Phi_4$ | 1-3-3                             |                                                              |
| 1d-R  | $\Phi_1XX\Phi_2XX\Phi_3XX\Phi_4$ | 1-3-2                             |                                                              |

* $\Phi$ is Leu, Val, Ile, Phe, or Met and X is any amino acid.

bSome NES sequences match multiple consensus patterns. CRM1-bound crystal structures of the NESs noted here reveal the correct consensus classes (Dong et al., 2009; Monecke et al., 2009; Guttler et al., 2010; Koyama et al., 2014; Fung et al., 2015, 2017; Baumhardt et al., 2020).

Uses a Thr instead of Val as $\Phi_1$ (Fung et al., 2017).
References

Baumhardt JM, Walker JS, Lee Y, Shaky B, Brautigam CA, Lapalombella R, Grishin N, Chook YM (2020). Recognition of nuclear export signals by CRM1 carrying the oncogenic E571K mutation. Mol Biol Cell 31, 1879–1891, 1113mbcE20040233.

Boons E, Vanstrees E, Jacquemyn M, Nogueira TC, Neggers JE, Vercruyss T, van den Oord J, Tamir S, Shacham S, Landesman Y, et al. (2015). Human Exportin-1 is a target for combined therapy of HIV and AIDS related lymphoma. EBioMedicine 2, 1102–1113.

Dong X, Biswas A, Suel KE, Jackson LK, Martinez R, Gu H, Chook YM (2009). Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature 458, 1136–1141.

Duffraisse M, Paul R, Carnesecchi J, Hudry B, Banreot J, Ajuria L, Lohmann I, Merabet S (2020). Role of a versatile peptide motif controlling Hox nuclear export and autophagy in the Dro sophila fat body. J Cell Sci 133.

Etchin J, Sun Q, Kentsis A, Farmer A, Zhang ZC, Sanda T, Mansour MR, Duffraisse M, Paul R, Carnesecchi J, Hudry B, Banreot J, Ajuria L, Lohmann I, Merabet S (2020). Anti-leukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia 27, 66–74.

Fung HY, Fu SC, Brautigam CA, Chook YM (2015). Structural determinants of nuclear export signal orientation in binding to exportin CRM1. Elife 4.

Fung HY, Fu SC, Chook YM (2017). Nuclear export receptor CRM1 recognizes diverse conformations in nuclear export signals. Elife 6.

Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O’Meara MJ, Rezelj VV, Guo JZ, Swaney DL, et al. (2020). A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583, 459–468.

Guttler T, Madl T, Neumann P, Deichsel D, Corsini L, Monecke T, Ficner R (2009). NES consensus redefined by structures of PKI-type and Rev-type nuclear export signals bound to CRM1. Nat Struct Mol Biol 16, 1367–1376.

Haines JD, Herbin O, de la Hera B, Vidaurre OG, Moy GA, Sun Q, Fung HY, Albrecht S, Alexandropoulos K, McCauley D, et al. (2015). Nuclear export inhibitors avert progression in preclinical models of inflammatory demyelination. Nat Neurosci 18, 511–520.

Kashyap T, Argueta C, Aboukameel A, Unger TJ, Klebanov B, Mohammad RM, Muqbil I, Azmi AS, Drolen C, Senapedis W, et al. (2016). Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-kappaB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death. Oncotarget 7, 78883–78895.

Kim J, McMillan E, Kim HS, Venkateswaran N, Makkar G, Rodriguez-Canales J, Villalobos P, Neggers JE, Mendiratta S, Wei S, et al. (2016). XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. Nature 538, 114–117.

Kim JY, Shen S, Dietz K, He Y, Howell O, Reynolds R, Casaccia P (2010). HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat Neurosci 13, 180–189.

Koyama M, Shirai N, Matsuura Y (2014). Structural insights into how Yrb2p accelerates the assembly of the Xpo1p nuclear export complex. Cell Rep 9, 983–995.

Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta S, et al. (2012). Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 120, 4621–4634.

Li A, Zou F, Fu H, Cui G, Yang P, Wu Q, Gu X (2013). Upregulation of CRM1 relates to neuronal apoptosis after traumatic brain injury in adult rats. J Mol Neurosci 51, 208–218.

Mathew C, Ghildyal R (2017). CRM1 inhibitors for antiviral therapy. Front Microbiol 8, 1171.

Monecke T, Guttler T, Neumann P, Dickmanns A, Gorlich D, Ficner R (2009). Crystal structure of the nuclear export receptor CRM1 in complex with Snurportin1 and RanGTP. Science 324, 1087–1091.

Perwitasari O, Johnson S, Yan X, Howeth E, Shacham S, Landesman Y, Baloglu E, McCauley D, Tamir S, Tompkins SM, Tripp RA (2014). Ver dinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo. J Virol 88, 10228–10243.

Sendino M, Omaetxebarria MJ, Prieto G, Rodriguez JA (2020). Using a simple cellular assay to map NES motifs in cancer-related proteins, gain insight into CRM1-mediated NES export, and search for NES-harboring micro peptides. Int J Mol Sci 21.

Tajir N, De La Pena I, Acosta SA, Kaneko Y, Tamir S, Landesman Y, Carlson R, Shacham S, Borlongan CV (2016). A nuclear attack on traumatic brain injury: sequestration of cell death in the nucleus. CNS Neurosci Ther 22, 306–315.

Taylor J, Sendino M, Gorelick AN, Pastore A, Chang MT, Penson AV, Gavrila BI, Stewart C, Melnik EM, Herrejon Chavez F, et al. (2019). Altered nuclear export signal recognition as a driver of oncogenesis. Cancer Discov 9, 1452–1467.

Wang XZ, Feng Y, Han YF, Bian Y, Liang Y, Wen HM, Wu H (2020). Budlelin A methylacrylate demonstrates potent activity against triple-negative breast cancer by targeting IkappaBalpha kinase and exportin-1. Toxicol Appl Pharmacol 408, 115263.

Wang AF, Liu H (2019). The past, present, and future of CRM1/XPO1 inhibitors. Stem Cell Investig 6, 6.

Xu D, Grishin NV, Chook YM (2012). NESdb: a database of NES-containing CRM1 cargoes. Mol Biol Cell 23, 3673–3676.

Xu D, Marquis K, Pei J, Fu SC, Cagatay T, Grishin NV, Chook YM (2015). LocNES: a computational tool for locating classical NESs in CRM1 cargo proteins. Bioinformatics 31, 1357–1365.

Zhang Y, Wang J, Henderson MJ, Yang F, Hagen BM, Siddique T, Vogel BE, Deng HX, Fang S (2017). Nuclear export of misfolded SOD1 mediated by a normally buried NES-like sequence reduces proteotoxicity in the nucleus. Elife 6.

Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F (2020). Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov 6, 14.